BioSpace News Archive

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under “SNSS”).

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December 31, 2020 and provided 2021 guidance.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights.

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat Patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2020 financial results.

- LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December 31, 2020 – - Conference call to be hosted today at 4:30 p.m. ET -

Commencing on March 11, 2021, the virtual conference will host a series of in-depth presentations with leading industry experts who will discuss how their companies are impacting and shaping the future of mental health care.

FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic and enterprise imaging and integration, announced that its Fujifilm Systems Integration business launched an American Institute of Architects accredited continuing education course titled, “Design Considerations for Technological Advancements in Operating Room Systems Integration.”

Multisystem inflammatory syndrome in children (MIS-C) was first formally recognized in May 2020 as a post-infectious syndrome in children exposed to the SARS-CoV-2 coronavirus

Renew Biopharma Inc., a preclinical drug discovery company, today announced a licensing agreement with Hypercann Agrogenetics Inc. giving Hypercann rights to use Renew’s proprietary engineered enzymes to modify Cannabis plants for improved profiles of cannabinoids.